Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Short term Debt (2020 - 2023)

Historic Short term Debt for GeneDx Holdings (WGS) over the last 4 years, with Q1 2023 value amounting to $4.3 million.

  • GeneDx Holdings' Short term Debt rose 3330.24% to $4.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $4.3 million, marking a year-over-year increase of 3330.24%. This contributed to the annual value of $3.6 million for FY2022, which is 3698.06% up from last year.
  • As of Q1 2023, GeneDx Holdings' Short term Debt stood at $4.3 million, which was up 3330.24% from $3.6 million recorded in Q4 2022.
  • In the past 5 years, GeneDx Holdings' Short term Debt ranged from a high of $4.3 million in Q1 2023 and a low of $797000.0 during Q1 2021
  • In the last 4 years, GeneDx Holdings' Short term Debt had a median value of $2.1 million in 2022 and averaged $2.3 million.
  • Examining YoY changes over the last 5 years, GeneDx Holdings' Short term Debt showed a top increase of 30614.81% in 2022 and a maximum decrease of 2828.07% in 2022.
  • Over the past 4 years, GeneDx Holdings' Short term Debt (Quarter) stood at $1.4 million in 2020, then surged by 84.07% to $2.6 million in 2021, then surged by 36.98% to $3.6 million in 2022, then increased by 20.09% to $4.3 million in 2023.
  • Its Short term Debt was $4.3 million in Q1 2023, compared to $3.6 million in Q4 2022 and $1.8 million in Q3 2022.